News | April 22, 2024
Evotech and Variant Bio partner to develop fibrosis treatment
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
To create leading company developing medicines targeting metalloenzymes
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
